BackGreenLight Biosciences Overview

GreenLight Biosciences Receivables

GreenLight Biosciences's receivables is $0.

Get informed when a big investor buys or sells

+ Follow
Receivables
$0.00
↓ 100.00% YoYΔ $-5.00M vs prior year quarter

Peer average

Loading

GreenLight Biosciences Receivables History

Loading

GreenLight Biosciences vs. peers: Receivables Comparison

Loading

GreenLight Biosciences Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

GreenLight Biosciences (GRNA) FAQ

GreenLight Biosciences posts a receivables of $0 as of March 2023. That compares with $5M in the prior-year period — down 100.0% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, GreenLight Biosciences's receivables was $5M. The latest reading is $0 — a 100.0% year-over-year decrease (period ending March 2023). Use the history and growth charts on this page for a longer lookback.

Receivables is one piece of GreenLight Biosciences's financial statement story. At $0, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for GRNA's receivables usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; GreenLight Biosciences's other metric pages and overview cover the third.